Crescent Biopharma, Inc. (CBIO)
CBIO Stock Price Chart
Explore Crescent Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze CBIO price movements and trends.
CBIO Company Profile
Discover essential business fundamentals and corporate details for Crescent Biopharma, Inc. (CBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jan 2014
Employees
44.00
Website
https://crescentbiopharma.comCEO
Joshua T. Brumm
Description
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO Financial Timeline
Browse a chronological timeline of Crescent Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.74, while revenue estimate is $357.14k.
Earnings released on 29 Apr 2026
EPS came in at -$0.70 surpassing the estimated -$0.85 by +17.65%, while revenue for the quarter reached $1.00m , beating expectations by +180.00%.
Earnings released on 26 Feb 2026
EPS came in at -$4.01 falling short of the estimated -$2.22 by -80.63%, while revenue for the quarter reached $10.84m , beating expectations by +8.44%.
Earnings released on 6 Nov 2025
EPS came in at -$1.27 falling short of the estimated -$1.01 by -25.74%.
Earnings released on 31 Jul 2025
EPS came in at -$4.93 falling short of the estimated -$2.69 by -83.27%.
Stock split effective on 16 Jun 2025
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 13 Feb 2025
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $54.09k .
Earnings released on 13 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%.
Earnings released on 8 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%.
Earnings released on 9 May 2024
EPS came in at -$0.17 falling short of the estimated -$0.16 by -6.25%.
Earnings released on 27 Mar 2024
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%, while revenue for the quarter reached $10.00k .
Earnings released on 3 Nov 2023
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 2 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%.
Earnings released on 3 May 2023
EPS came in at -$0.17 matching the estimated -$0.17.
Earnings released on 29 Mar 2023
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%, while revenue for the quarter reached $75.00 .
Earnings released on 9 Nov 2022
EPS came in at -$0.16 surpassing the estimated -$0.26 by +38.46%.
Earnings released on 3 Aug 2022
EPS came in at -$0.25 surpassing the estimated -$0.29 by +13.79%, while revenue for the quarter reached $75.00k .
Earnings released on 28 Apr 2022
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%.
Earnings released on 3 Mar 2022
EPS came in at -$0.33 falling short of the estimated -$0.31 by -6.45%, while revenue for the quarter reached $18.00k .
Earnings released on 2 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%, while revenue for the quarter reached $86.56k , beating expectations by +6.67%.
Earnings released on 5 Aug 2021
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $142.00 , missing expectations by -8.39%.
CBIO Stock Performance
Access detailed CBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
